



Action Kidney Cancer



Access to Kidney Cancer Medicines in the UK – September 2024

Trade name <i>Manufacturer</i>	Generic name	How it works	Indication	Availability
First-line treatments				
Welireg <i>MSD</i>	Belzutifan	Hypoxia-inducible factor 2-alpha (HIF2α) inhibitor Oral medication	Treatment for von Hippel-Lindau (VHL) disease associated renal cell carcinoma (RCC) for patients unable to have localised procedures	Available on the NHS in England and Wales under managed access . Available on the NHS in Scotland under a Patient Access Scheme (PAS)
Keytruda <i>MSD</i>	Pembrolizumab	Immunotherapy: anti-PD1 checkpoint inhibitor infusion	Adjuvant treatment for locally advanced moderate to high risk RCC	Available on the NHS
Kisplyx plus Keytruda <i>Eisai/MSD</i>	Lenvatinib in combination with pembrolizumab	Targeted therapy plus immunotherapy: VEGF tyrosine kinase inhibitor (TKI) plus anti-PD1 checkpoint inhibitor Infusion plus oral medication	First-line treatment for advanced RCC	Available on the NHS in England and Wales. Restricted access on the NHS under a Patient Access Scheme (PAS) in Scotland
Cabometyx plus Opdivo <i>Ipsen/BMS</i>	Cabozantinib in combination with nivolumab	Targeted therapy plus immunotherapy: VEGF tyrosine kinase inhibitor (TKI) plus anti-PD1 checkpoint inhibitor Oral medication plus infusion	First-line treatment for advanced RCC	Available on the NHS in England and Wales. Available on the NHS in Scotland under a Patient Access Scheme (PAS)
Bavencio plus Inlyta <i>Merck/Pfizer</i>	Avelumab in combination with axitinib	Immunotherapy plus targeted therapy: Anti-PD-L1 checkpoint inhibitor plus VEGF tyrosine kinase inhibitor (TKI) Infusion plus oral medication	First-line treatment for advanced/metastatic RCC	Available via the Cancer Drugs Fund (CDF) for patients in England and Wales. Available on the NHS in Scotland
Keytruda plus Inlyta <i>MSD/Pfizer</i>	Pembrolizumab in combination with axitinib	Immunotherapy plus targeted therapy: Anti-PD1 checkpoint inhibitor plus VEGF tyrosine kinase inhibitor (TKI)	First-line treatment for advanced RCC	Restricted access on the NHS under a Patient Access Scheme (PAS) in Scotland. Not available on the NHS in England and Wales

Action Kidney Cancer

Registered charity in England and Wales (1164238) and Scotland (SC051330)

Website: www.actionkidneycancer.org | Email: support@actionkidneycancer.org | Helpline: 0800 121 8721

		Infusion plus oral medication		
Opdivo plus Yervoy <i>BMS</i>	Nivolumab in combination with ipilimumab	Immunotherapy: Anti-PD1 checkpoint inhibitor plus anti-CTLA4 inhibitor Infusion	First-line treatment for intermediate and poor risk advanced RCC	Available on the NHS
Sutent <i>Pfizer</i>	Sunitinib	Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Oral medication	First-line treatment for metastatic RCC	Available on the NHS
Votrient <i>Novartis</i>	Pazopanib	Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Oral medication	First-line treatment for metastatic RCC	Available on the NHS
Cabometyx <i>Ipsen</i>	Cabozantinib	Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Oral medication	First-line treatment for locally advanced/metastatic RCC	Available on the NHS
Fotivda <i>Aveo/Eusa</i>	Tivozanib	Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Oral medication	First-line treatment for metastatic RCC	Available on the NHS
Second-line treatments				
Kisplyx plus Afinitor <i>Eisai, Novartis</i>	Lenvatinib in combination with everolimus	Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) plus mTOR inhibitor Oral medication	Second-line treatment for advanced RCC	Available on the NHS
Inlyta <i>Pfizer</i>	Axitinib	Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Oral medication	Second-line treatment for advanced RCC	Available on the NHS
Second line and beyond treatments				
Opdivo <i>BMS</i>	Nivolumab	Immunotherapy: Anti-PD1 checkpoint inhibitor	Second/third-line treatment for advanced/metastatic RCC	Available on the NHS
Cabometyx <i>Ipsen</i>	Cabozantinib	Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Oral medication	Second/third-line treatment for advanced RCC after VEGF-TKI treatment	Available on the NHS
Afinitor <i>Novartis</i>	Everolimus	Targeted therapy: mTOR inhibitor Oral medication	Second/third-line treatment for advanced RCC	Available on the NHS in England, Scotland and Wales
Other treatments for advanced kidney cancer				

Action Kidney Cancer

Registered charity in England and Wales (1164238) and Scotland (SC051330)

Website: www.actionkidneycancer.org | Email: support@actionkidneycancer.org | Helpline: 0800 121 8721

Proleukin <i>Clinigen</i>	Interleukin 2 (IL 2)	Immunotherapy: Cytokine Infusion	Advanced/metastatic RCC	Available to pre-selected patients only at specialist research sites (Christie Hospital, Manchester). Not funded by the NHS
Torisel <i>Pfizer</i>	Temsirolimus	Targeted therapy: mTOR inhibitor Oral medication	First-line treatment for advanced RCC of poor prognosis	Not routinely available on the NHS Access via individual funding request*
Avastin <i>Roche</i>	Bevacizumab	Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Infusion	First-line treatment for advanced/metastatic RCC in combination with interferon alpha	Not routinely available on the NHS Access via individual funding request*
Nexavar <i>Bayer</i>	Sorafenib	Targeted therapy: VEGF tyrosine kinase inhibitor (TKI) Oral medication	First/second-line treatment for advanced/metastatic RCC	Not routinely available on the NHS Access via individual funding request*
Tecentriq plus Avastin <i>Roche</i>	Atezolizumab in combination with bevacizumab	Immunotherapy plus targeted therapy: Anti-PD-L1 checkpoint inhibitor plus VEGF tyrosine kinase inhibitor (TKI) Infusion	First-line treatment for locally advanced/metastatic RCC	Appraisal suspended
Xgeva <i>Amgen</i>	Denosumab	Immunotherapy: RANK ligand inhibitor Injection	Cancer that has spread to the bones as an alternative to bisphosphonates	Available on the NHS

Clinical Trials for Kidney Cancer - Please go to our [clinical trials database](#) for a complete list of all clinical trials for kidney cancer in the UK:

*Individual funding requests may be submitted via the following route:

- England and Northern Ireland: [Individual Funding Request \(IFR\)](#)
- Wales: [Individual Patient Funding Request \(IPFR\)](#)
- Scotland: [Individual Patient Treatment Request \(IPTR\)](#)